[go: up one dir, main page]

CA2378954A1 - Gene il-1l1 et produits polypeptidiques - Google Patents

Gene il-1l1 et produits polypeptidiques Download PDF

Info

Publication number
CA2378954A1
CA2378954A1 CA002378954A CA2378954A CA2378954A1 CA 2378954 A1 CA2378954 A1 CA 2378954A1 CA 002378954 A CA002378954 A CA 002378954A CA 2378954 A CA2378954 A CA 2378954A CA 2378954 A1 CA2378954 A1 CA 2378954A1
Authority
CA
Canada
Prior art keywords
gene
nucleic acid
seq
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002378954A
Other languages
English (en)
Inventor
Martin Nicklin
Jenny Barton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of CA2378954A1 publication Critical patent/CA2378954A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/545IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La présente invention concerne la découverte de nouveaux gènes codés par un locus d'interleukine-1. Le gène IL-1L1 est placé dans l'intervalle situé entre les gènes codant l'antagoniste de récepteur IL-1 .beta. et IL-1 et code un polypeptide qui est homologue aux protéines d'antagoniste IL-1 et d'agoniste IL-1. L'invention traite de procédés de dosage, de procédés diagnostiques et thérapeutiques utilisant ces molécules.
CA002378954A 1999-07-16 2000-07-17 Gene il-1l1 et produits polypeptidiques Abandoned CA2378954A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14429899P 1999-07-16 1999-07-16
US60/144,298 1999-07-16
PCT/US2000/019508 WO2001005974A2 (fr) 1999-07-16 2000-07-17 Gène il-1l1 et produits polypeptidiques

Publications (1)

Publication Number Publication Date
CA2378954A1 true CA2378954A1 (fr) 2001-01-25

Family

ID=22507973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002378954A Abandoned CA2378954A1 (fr) 1999-07-16 2000-07-17 Gene il-1l1 et produits polypeptidiques

Country Status (6)

Country Link
EP (1) EP1200593A2 (fr)
JP (1) JP2003523943A (fr)
AU (1) AU6219400A (fr)
CA (1) CA2378954A1 (fr)
IL (1) IL147534A0 (fr)
WO (1) WO2001005974A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035268A1 (fr) 1998-01-09 1999-07-15 Immunex Corporation Adn codant il-1 delta et polypeptides il-1 delta
US20030100031A1 (en) * 2001-06-11 2003-05-29 Steven Dower Integrative assays for monitoring molecular assembly events
EP1585482A4 (fr) * 2002-09-25 2009-09-09 Genentech Inc Nouvelles compositions et methodes de traitement du psoriasis
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
CA2662549C (fr) * 2006-09-08 2014-10-28 Amgen Inc. Variants de la famille il-1
EP3554343A1 (fr) * 2016-12-14 2019-10-23 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977779A1 (fr) * 1997-04-21 2000-02-09 Schering Corporation Cytokines de mammifere; reactifs et procedes connexes
WO1999035268A1 (fr) * 1998-01-09 1999-07-15 Immunex Corporation Adn codant il-1 delta et polypeptides il-1 delta
AU769262B2 (en) * 1998-04-03 2004-01-22 Arca Biopharma, Inc. A interleukin-1 receptor antagonist and uses thereof
AU5772299A (en) * 1998-08-07 2000-02-28 Millennium Pharmaceuticals, Inc. Novel molecules of the tango-93-related protein family and uses thereof
WO2000020595A1 (fr) * 1998-10-08 2000-04-13 Zymogenetics, Inc. Homologues de l'interleukine-1
JP5456222B2 (ja) * 1998-12-23 2014-03-26 ジェネンテック, インコーポレイテッド Il−1関連ポリペプチド

Also Published As

Publication number Publication date
IL147534A0 (en) 2002-08-14
WO2001005974A3 (fr) 2001-05-10
WO2001005974A9 (fr) 2001-06-28
EP1200593A2 (fr) 2002-05-02
JP2003523943A (ja) 2003-08-12
WO2001005974A2 (fr) 2001-01-25
AU6219400A (en) 2001-02-05

Similar Documents

Publication Publication Date Title
US5800998A (en) Assays for diagnosing type II diabetes in a subject
US5807708A (en) Conservin nucleic acid molecules and compositions
US6143491A (en) Therapeutic compositions and methods and diagnostic assays for type II diabetes involving HNF-1
US6833239B1 (en) Methods to identify modulators of FKHL7 DNA-binding activity
US20050171338A1 (en) Mammalian tribbles signaling pathways and methods and reagents related thereto
US6399760B1 (en) RP compositions and therapeutic and diagnostic uses therefor
US20060183161A1 (en) IL-ILI gene and polypeptide products
CA2378954A1 (fr) Gene il-1l1 et produits polypeptidiques
US6518411B1 (en) RGS compositions and therapeutic and diagnostic uses therefor
US20010041353A1 (en) Novel SSP-1 compositions and therapeutic and diagnostic uses therefor
US20030022170A1 (en) Novel fibroblast growth factors and therapeutic and diagnostic uses therefor
EP0942975A1 (fr) Proteine associee au glaucome, acide nucleique correspondant et leurs utilisations diagnostiques et therapeutiques
WO1998046756A9 (fr) Compositions de proteines secretees ssp-1 et utilisations de ces compositions a des fins diagnostiques et therapeutiques
WO1998046748A1 (fr) Compositions therapeutiques et dosages de diagnostic pour des affections liees a la trbp
US6207450B1 (en) Glaucoma therapeutics and diagnostics based on a novel human transcription factor
US6008014A (en) Method of making lipid metabolic pathway compositions
US6271026B1 (en) Glaucoma compositions
WO1998009979A9 (fr) Compositions relatives a la voie metabolique lipidique et utilisations therapeutiques et diagnostiques de telles compositions
WO1998021363A1 (fr) Compositions et therapies utilisables contre le diabete de type ii lie au hnf-4
AU2002243454A1 (en) Mammalian tribbles signaling pathways and methods and reagents related thereto
US6306586B1 (en) Methods and compositions for the diagnosis and treatment of cataracts
AU3556402A (en) Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses

Legal Events

Date Code Title Description
FZDE Discontinued